Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Endothelial GDF15 deficiency enhances barrier function and mitigates pulmonary fibrosis
Kristen Raffensperger, Marta Bueno, Brian J. Philips, Megan Miller, Máté Katona, Shuai Yuan, Adriana Estrada-Bernal, Byron Chuan, Pavan Suresh, Stephanie Taiclet, Scott Hahn, Yingze Zhang, Jonathan K. Alder, Seyed Mehdi Nouraie, Daniel J. Kass, Oliver Eickelberg, Adam C. Straub
Kristen Raffensperger, Marta Bueno, Brian J. Philips, Megan Miller, Máté Katona, Shuai Yuan, Adriana Estrada-Bernal, Byron Chuan, Pavan Suresh, Stephanie Taiclet, Scott Hahn, Yingze Zhang, Jonathan K. Alder, Seyed Mehdi Nouraie, Daniel J. Kass, Oliver Eickelberg, Adam C. Straub
View: Text | PDF
Research Article Cell biology Pulmonology Vascular biology

Endothelial GDF15 deficiency enhances barrier function and mitigates pulmonary fibrosis

  • Text
  • PDF
Abstract

Pulmonary fibrosis is frequently accompanied by pulmonary hypertension, which can occur disproportionate to the extent of fibrosis, suggesting a fibrosis-independent vascular remodeling process. Here, we demonstrated that plasma growth differentiation factor 15 (GDF15) is elevated across diverse fibrotic lung disease subtypes and correlates with markers of elevated right heart pressures but not pulmonary function indices, indicating a possible link to endothelial cell dysfunction. To investigate the import of endothelial GDF15 as a modifier of lung fibrosis pathogenesis, we generated endothelial cell–specific Gdf15-KO mice, which showed protection from bleomycin-induced lung injury and fibrosis, with preserved lung function. RNA-seq of human pulmonary microvascular endothelial cells revealed altered expression of barrier-regulatory genes in GDF15-deficient endothelial cells compared with controls. Functional studies confirmed that GDF15 knockdown attenuates thrombin-induced barrier disruption by reducing cytosolic Ca2+ responses. Together, these findings implicate endothelial GDF15 as a modifier of vascular permeability and Ca2+ signaling and a contributor to lung injury and fibrosis.

Authors

Kristen Raffensperger, Marta Bueno, Brian J. Philips, Megan Miller, Máté Katona, Shuai Yuan, Adriana Estrada-Bernal, Byron Chuan, Pavan Suresh, Stephanie Taiclet, Scott Hahn, Yingze Zhang, Jonathan K. Alder, Seyed Mehdi Nouraie, Daniel J. Kass, Oliver Eickelberg, Adam C. Straub

×

Figure 3

Murine endothelial KO of Gdf15 is protective.

Options: View larger image (or click on image) Download as PowerPoint
Murine endothelial KO of Gdf15 is protective.
(A) Schematic depicting ex...
(A) Schematic depicting experimental timeline. Endothelial Gdf15-KO was performed over 2 cohorts of mice. (B) Percent weight loss from baseline across EndoGDF15 WT and EndoGDF15-KO mice treated with either intratracheal saline or bleomycin (Day 0). n = 5 per group (EndoGDF15 WT Saline), n = 10 per group otherwise. (C) Pulmonary function data acquired from EndoGDF15 WT and EndoGDF15-KO mice at day 14. (D) Serum GDF15 levels from EndoGDF15 WT and EndoGDF15-KO mice, collected at day 14, measured using a Luminex assay. (E) Representative picrosirius red staining of murine histologic sections from EndoGDF15 WT (n = 10) and EndoGDF15-KO (n = 10) mice, treated with either intratracheal saline (n = 5 per group) or bleomycin (n = 5 per group). Scale bar in whole lung: 2 mm. Scale bar in zoom: 200 μm. (F) Quantitative analysis of trichrome-stained histologic murine lung sections from EndoGDF15 WT (n = 18) and EndoGDF15 KO (n = 18) mice, treated with either intratracheal saline or bleomycin. (G) Quantitative analysis of hydroxyproline in lung tissue from bleomycin-treated EndoGDF15 WT and EndoGDF15-KO mice. One-way repeated measures ANOVA (B), 2-way ANOVA with post hoc Holm-Šídák’s multiple comparison test (C), 2-way ANOVA as well as unpaired 2-tailed t test between 2 groups (D), 2-way ANOVA (F), Welch’s t test (G). ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts